Activin receptor type IIB ligands (ACVR2B ligands)

Activin receptor type IIB (ACVR2B) ligands, including Activin A, Activin B, Myostatin (GDF8), and Growth Differentiation Factor 11 (GDF11), are members of the Transforming Growth Factor-beta (TGF-beta) superfamily that play critical roles in regulating growth and differentiation (UniProt, 2024). These ligands bind to the ACVR2B receptor, a transmembrane serine/threonine kinase, to initiate intracellular signaling through the SMAD2/3 pathway (Nature Medicine, 2014). In hematopoietic tissues, ligands like GDF11 and Activin B act as negative regulators of late-stage erythropoiesis; their overactivation leads to ineffective red blood cell production in conditions such as beta-thalassemia and myelodysplastic syndromes (FDA Reblozyl PI, 2023). In the vasculature, an imbalance in activin signaling contributes to the pathological remodeling seen in pulmonary arterial hypertension (NEJM, 2024). Therapeutic strategies targeting these ligands primarily utilize ligand traps, such as Luspatercept and Sotatercept, which are recombinant fusion proteins consisting of the extracellular domain of activin receptors fused to an IgG Fc domain (FDA Winrevair PI, 2024). These traps sequester circulating ligands, preventing their interaction with cell-surface receptors and thereby restoring homeostatic signaling in bone marrow and vascular tissues.

Other names

MyostatinGDF8GDF11Activin AActivin BGrowth differentiation factor 11Growth differentiation factor 8TGF-beta superfamily ligands

Ligand sequestration via soluble receptor fusion proteins (ligand traps), preventing binding to endogenous ACVR2B and subsequent SMAD2/3 signaling.